The appellate court sided with Regeneron, agreeing with the pharma that a district court had wrongly dismissed its antitrust claims against Novartis because anti-VEGF therapies sold in pre-filled syringes (PFS) constitute their own and distinct market versus therapies sold in vials.
Tag Archive for: Lucentis
For Sandoz, Monday’s deal with Coherus represents its first major contract since spinning out of Novartis in October 2023.
Citing anonymous sources familiar with the matter, a Bloomberg reported that Novartis has already started contacting likely buyers and expects to attract private equity and strategic bidders.
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
